Abstract:Background Triple-negative breast cancer (TNBC) is a category of breast cancer characterized with high molecular heterogeneity. Owing to the lack of effective therapeutic strategies, patients with TNBC have a poor prognosis. Paris saponin VII (PSVII), a steroidal saponin extracted from the rhizome of Trichillium tschonoskii Maxim, exhibits excellent anti-cancer activity in a variety of solid tumors. However, the role and potential mechanism of PSVII against TNBC remain unexplored. Purpose This study aimed to elucidate the therapeutic effects of PSVII against TNBC and explore the potential mechanism of action. Methods We combined the analysis of public single-cell sequencing data with weighted gene co-expression network analysis (WGCNA) to identity differentially expressed genes (DEGs) that distinguished malignant and normal epithelial cells in TNBC. Subsequently, the biological features of DEGs in TNBC were evaluated. Gene set enrichment analysis (GSEA) was used to define potential pathways associated with the DEGs. The pharmacological activity of PSVII for TNBC was evidenced via in vitro and in vivo experiments, and molecular docking, molecular dynamics (MD), surface plasmon resonance (SPR) assay and western blotting were employed to confirm the relative mechanisms. Results Single-cell sequencing and WGCNA revealed STMN1 as a pivotal biomarker of TNBC. STMN1 overexpression in TNBC was associated with poor patient prognosis. GSEA revealed a significant accumulation of STMN1 within the MAPK signaling pathway. Furthermore, In vitro experiments showed that PSVII showed significantly suppressive actions on the proliferation, migration and invasion abilities for TNBC cells, while inducing apoptosis. Molecular docking, MD analysis and SPR assay indicated a robust interaction between PSVII and the MEK protein. Western blotting revealed that PSVII may inhibit tumor progression by suppressing the phosphorylation of MEK1/2 and the downstream phosphorylation of ERK1/2 and STMN1. Intraperitoneal injection of PSVII (10 mg/kg) notably reduced tumor growth by 71.26 % in a 4T1 xenograft model. Conclusion In our study, the systems biology method was used to identify potential therapeutic targets for TNBC. In vitro and in vivo experiments demonstrated PSVII suppresses cancer progression by targeting the MEK/ERK/STMN1 signaling axis. For the first time, the inhibition of STMN1 phosphorylation has been indicated as a possible mechanism for the anticancer effects of PSVII. These results emphasize the potential value of PSVII as a promising anti-cancer drug candidate for further development in the field of TNBC therapeutics.

Paris saponin VII, a direct activator of AMPK, induces autophagy and exhibits therapeutic potential in non-small-cell lung cancer

Paris saponin VII, a Hippo pathway activator, induces autophagy and exhibits therapeutic potential against human breast cancer cells

Paris Saponin VII Reverses Chemoresistance in Breast MCF-7/ADR Cells.

Paris saponin VII inhibits triple-negative breast cancer by targeting the MEK/ERK/STMN1 signaling axis

Polyphyllin I activates AMPK to suppress the growth of non-small-cell lung cancer via induction of autophagy

Paris saponin VII from trillium tschonoskii reverses multidrug resistance of adriamycin-resistant MCF-7/ADR cells via P-glycoprotein inhibition and apoptosis augmentation

Ecliptasaponin A induces apoptosis through the activation of ASK1/JNK pathway and autophagy in human lung cancer cells.

Ethoxysanguinarine, a Novel Direct Activator of AMP-Activated Protein Kinase, Induces Autophagy and Exhibits Therapeutic Potential in Breast Cancer Cells

Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment

Paris saponin VII promotes ferroptosis to inhibit breast cancer via Nrf2/GPX4 axis

Paris Saponin I Induces Apoptosis Via Increasing the Bax/Bcl-2 Ratio and Caspase-3 Expression in Gefitinib-Resistant Non-Small Cell Lung Cancer in Vitro and in Vivo.

Paris Saponin VII Enhanced the Sensitivity of HepG2/ADR Cells to ADR Via Modulation of PI3K/AKT/MAPK Signaling Pathway.

Mechanism of Paris polyphylla saponin II inducing autophagic to inhibit angiogenesis of cervical cancer

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

Resveratrol, an activator of SIRT1, induces protective autophagy in non-small-cell lung cancer via inhibiting Akt/mTOR and activating p38-MAPK

Identification and validation of autophagy-related genes influenced by paris polyphylla in tongue cancer using network pharmacology

Paris Saponins Enhance Radiosensitivity in A Gefitinib-Resistant Lung Adenocarcinoma Cell Line by Inducing Apoptosis and G(2)/M Cell Cycle Phase Arrest

Induction of Autophagy and Activation of Sestrin-2/LKB1/AMPK Signalling

SSPH I, A Novel Anti-cancer Saponin, Inhibits EMT and Invasion and Migration of NSCLC by Suppressing MAPK/ERK1/2 and PI3K/AKT/mTOR Signaling Pathways

Platycodin-D Induced Autophagy in Non-Small Cell Lung Cancer Cells via PI3K/Akt/mTOR and MAPK Signaling Pathways

Polyphyllin II induced apoptosis of NSCLC cells by inhibiting autophagy through the mTOR pathway